EE95 Cost-Effectiveness Analysis of Pemigatinib for the Treatment of Adult Patients with Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement That Have Progressed After Systemic Therapy in Greece
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.366
https://www.valueinhealthjournal.com/article/S1098-3015(23)03496-4/fulltext
Title :
EE95 Cost-Effectiveness Analysis of Pemigatinib for the Treatment of Adult Patients with Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement That Have Progressed After Systemic Therapy in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03496-4&doi=10.1016/j.jval.2023.09.366
First page :
Section Title :
Open access? :
No
Section Order :
12391